Agriculture Canada HEMP
Published by an arm of the Canadian Federal Government, this 22 page reports discusses the history of Hemp and the current status of the hemp industry in Canada.
CBD Legal Status
Lexaria engaged a law firm with experience in this field, to produce this legal opinion regarding the manufacturing, distribution and sale within the USA, of products containing CBD.
Congressional Research Service HEMP
This 29-page study was produced in 2013 by a specialist in agricultural policy for Members and Committees of Congress. It provides an excellent overview of the legal hemp industry.
Department of Justice Hemp Exemptions
Published in 2001 in the Federal Register, the document from the Drug Enforcement Administration discusses the exemptions its issued to its own interpretive rule, allowing for exemptions from the Controlled Substances Act for certain THC-containing products.
Global Tea Consumption
This 14-page document was published in 2009 and provides information on the history of tea and current global consumption and other trends.
Lexaria provides this proprietary document produced as a result of its engagement of a law firm with experience in this sector. It provides an overview of Generally Recognized As Safe (GRAS) policies w/r to the Federal Drug Administration (FDA).
Sources of Cannabis Case Reports and Studies
This bibliography makes more than 350 references to published articles or studies related to cannabis or cannabidiol and their relationship with various health conditions.
Tea Council Tea & Health Brochure
Like eating fruits, vegetables and other plant-based foods, regular tea consumption has been shown to have significant benefits. Did you know that tea is the second most popular beverage in the world next to water? Or that recent studies have associated two compounds in tea, L-theanine and caffeine, with cognitive benefits? This Tea Council brochure provides the answers.
United States Court of Appeals DEA vs. Hemp
This is the actual 2004 court opinion that found the DEA had overstepped its authority and may only enforce Schedule 1 regulation in the presence of marijuana or synthetic THC. The court concluded that:
- • (The DEA) “cannot regulate naturally-occurring THC not contained within or derived from marijuana- i.e., non-psychoactive hemp products – because non-psychoactive hemp is not included in Schedule I.”
- • “The DEA’s definition of “THC” contravenes the unambiguously expressed intent of Congerss in the CSA and cannot be upheld.”
United States Patent on Cannabinoids
This is the actual patent published in 1999 by the US Patent Office. The Assignee is “The United State of America as represented by the Department of Health and Human Services”. The Abstract reads:
“Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH.sub.3, and COCH.sub.3. ##STR1##”